582 related articles for article (PubMed ID: 22076945)
1. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy.
Connolly M; Mullan RH; McCormick J; Matthews C; Sullivan O; Kennedy A; FitzGerald O; Poole AR; Bresnihan B; Veale DJ; Fearon U
Arthritis Rheum; 2012 Apr; 64(4):1035-45. PubMed ID: 22076945
[TBL] [Abstract][Full Text] [Related]
2. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis.
O'Hara R; Murphy EP; Whitehead AS; FitzGerald O; Bresnihan B
Arthritis Rheum; 2004 Jun; 50(6):1788-99. PubMed ID: 15188355
[TBL] [Abstract][Full Text] [Related]
3. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade.
Rooney T; Roux-Lombard P; Veale DJ; FitzGerald O; Dayer JM; Bresnihan B
Ann Rheum Dis; 2010 Apr; 69(4):706-14. PubMed ID: 19460761
[TBL] [Abstract][Full Text] [Related]
4. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis.
Jain A; Nanchahal J; Troeberg L; Green P; Brennan F
Arthritis Rheum; 2001 Aug; 44(8):1754-60. PubMed ID: 11508425
[TBL] [Abstract][Full Text] [Related]
5. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
[TBL] [Abstract][Full Text] [Related]
6. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis.
Catrina AI; Lampa J; Ernestam S; af Klint E; Bratt J; Klareskog L; Ulfgren AK
Rheumatology (Oxford); 2002 May; 41(5):484-9. PubMed ID: 12011369
[TBL] [Abstract][Full Text] [Related]
8. Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model.
Connolly M; Marrelli A; Blades M; McCormick J; Maderna P; Godson C; Mullan R; FitzGerald O; Bresnihan B; Pitzalis C; Veale DJ; Fearon U
J Immunol; 2010 Jun; 184(11):6427-37. PubMed ID: 20435930
[TBL] [Abstract][Full Text] [Related]
9. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
[TBL] [Abstract][Full Text] [Related]
10. Association of tumor necrosis factor-α (G-308A) genetic variant with matrix metalloproteinase-9 activity and joint destruction in early rheumatoid arthritis.
Stojanovic S; Bojana Stamenkovic ; Stoimenov TJ; Nedovic J; Zivkovic V; Despotovic M; Pavlovic D
Clin Rheumatol; 2017 Jul; 36(7):1479-1485. PubMed ID: 28573370
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
12. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.
Moran EM; Mullan R; McCormick J; Connolly M; Sullivan O; Fitzgerald O; Bresnihan B; Veale DJ; Fearon U
Arthritis Res Ther; 2009; 11(4):R113. PubMed ID: 19627579
[TBL] [Abstract][Full Text] [Related]
13. The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis.
Smeets TJ; Dayer JM; Kraan MC; Versendaal J; Chicheportiche R; Breedveld FC; Tak PP
Arthritis Rheum; 2000 Feb; 43(2):270-4. PubMed ID: 10693865
[TBL] [Abstract][Full Text] [Related]
14. Piascledine modulates the production of VEGF and TIMP-1 and reduces the invasiveness of rheumatoid arthritis synoviocytes.
Cinelli M; Guiducci S; Del Rosso A; Pignone A; Del Rosso M; Fibbi G; Serratì S; Gabrielli A; Giacomelli R; Piccardi N; Matucci Cerinic M
Scand J Rheumatol; 2006; 35(5):346-50. PubMed ID: 17062432
[TBL] [Abstract][Full Text] [Related]
15. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.
Cunnane G; Fitzgerald O; Beeton C; Cawston TE; Bresnihan B
Arthritis Rheum; 2001 Oct; 44(10):2263-74. PubMed ID: 11665967
[TBL] [Abstract][Full Text] [Related]
16. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts.
Migita K; Kawabe Y; Tominaga M; Origuchi T; Aoyagi T; Eguchi K
Lab Invest; 1998 May; 78(5):535-9. PubMed ID: 9605178
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis.
Smeets TJ; Barg EC; Kraan MC; Smith MD; Breedveld FC; Tak PP
Ann Rheum Dis; 2003 Jul; 62(7):635-8. PubMed ID: 12810425
[TBL] [Abstract][Full Text] [Related]
18. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy.
Vandooren B; Kruithof E; Yu DT; Rihl M; Gu J; De Rycke L; Van Den Bosch F; Veys EM; De Keyser F; Baeten D
Arthritis Rheum; 2004 Sep; 50(9):2942-53. PubMed ID: 15457463
[TBL] [Abstract][Full Text] [Related]
19. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10.
Tolboom TC; Pieterman E; van der Laan WH; Toes RE; Huidekoper AL; Nelissen RG; Breedveld FC; Huizinga TW
Ann Rheum Dis; 2002 Nov; 61(11):975-80. PubMed ID: 12379519
[TBL] [Abstract][Full Text] [Related]
20. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
